To	O
achieve	O
this	O
goal	O
,	O
we	O
analyzed	O
data	O
from	O
a	O
curated	O
EHR	O
-	O
derived	O
real	O
-	O
world	O
dataset	O
to	O
compare	O
outcomes	O
in	O
a	O
cohort	O
of	O
women	O
with	O
hormone	O
-	O
receptor	O
positive	O
(	O
HR+	O
)	O
,	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2-negative	O
(	O
HER2-	O
)	O
metastatic	O
breast	O
cancer	O
(	O
mBC	O
)	O
who	O
received	O
first	O
-	O
line	O
letrozole	O
therapy	O
in	O
a	O
[P1]	O
real	O
-	O
world	O
[P2]	O
setting	O
with	O
those	O
in	O
the	O
control	O
arm	O
of	O
the	O
phase	O
3	O
PALOMA-2	O
trial	O
.	O
[	O

To	O
achieve	O
this	O
goal	O
,	O
we	O
analyzed	O
data	O
from	O
a	O
curated	O
EHR	O
-	O
derived	O
real	O
-	O
world	O
dataset	O
to	O
compare	O
outcomes	O
in	O
a	O
cohort	O
of	O
women	O
with	O
hormone	O
-	O
receptor	O
positive	O
(	O
HR+	O
)	O
,	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2-negative	O
(	O
HER2-	O
)	O
metastatic	O
breast	O
cancer	O
(	O
mBC	O
)	O
who	O
received	O
first	O
-	O
line	O
letrozole	O
therapy	O
in	O
a	O
real	O
-	O
world	O
setting	O
with	O
those	O
in	O
the	O
[P1]	O
control	O
arm	O
[P2]	O
of	O
the	O
phase	O
3	O
PALOMA-2	O
trial	O
.	O
[	O

13	O
]	O
An	O
inverse	O
probability	O
of	O
treatment	O
weighting	O
(	O
IPTW	O
)	O
approach	O
was	O
used	O
to	O
account	O
for	O
potential	O
baseline	O
differences	O
in	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
and	O
PALOMA-2	O
cohorts	O
,	O
which	O
allowed	O
retrospective	O
evaluation	O
of	O
the	O
comparability	O
of	O
the	O
realworld	O
and	O
traditional	O
RECIST	O
-	O
based	O
clinical	O
trial	O
endpoints	O
in	O
2	O
similar	O
cohorts	O
.	O
[	O

13	O
]	O
An	O
inverse	O
probability	O
of	O
treatment	O
weighting	O
(	O
IPTW	O
)	O
approach	O
was	O
used	O
to	O
account	O
for	O
potential	O
baseline	O
differences	O
in	O
the	O
real	O
-	O
world	O
and	O
[P1]	O
PALOMA-2	O
[P2]	O
cohorts	O
,	O
which	O
allowed	O
retrospective	O
evaluation	O
of	O
the	O
comparability	O
of	O
the	O
realworld	O
and	O
traditional	O
RECIST	O
-	O
based	O
clinical	O
trial	O
endpoints	O
in	O
2	O
similar	O
cohorts	O
.	O
[	O

13	O
]	O
An	O
inverse	O
probability	O
of	O
treatment	O
weighting	O
(	O
IPTW	O
)	O
approach	O
was	O
used	O
to	O
account	O
for	O
potential	O
baseline	O
differences	O
in	O
the	O
real	O
-	O
world	O
and	O
PALOMA-2	O
cohorts	O
,	O
which	O
allowed	O
retrospective	O
evaluation	O
of	O
the	O
comparability	O
of	O
the	O
[P1]	O
realworld	O
[P2]	O
and	O
traditional	O
RECIST	O
-	O
based	O
clinical	O
trial	O
endpoints	O
in	O
2	O
similar	O
cohorts	O
.	O
[	O

The	O
[P1]	O
real	O
-	O
world	O
[P2]	O
cohort	O
was	O
drawn	O
from	O
de	O
-	O
identified	O
patient	O
data	O
from	O
the	O
Flatiron	O
Health	O
database	O
,	O
a	O
longitudinal	O
,	O
demographically	O
and	O
geographically	O
diverse	O
database	O
derived	O
from	O
EHR	O
data	O
.	O
[	O

These	O
analyses	O
and	O
the	O
studies	O
included	O
in	O
these	O
analyses	O
(	O
NCT01740427	O
)	O
were	O
sponsored	O
by	O
Pfizer	O
Inc.	O
The	O
[P1]	O
real	O
-	O
world	O
[P2]	O
data	O
used	O
are	O
derived	O
from	O
the	O
Flatiron	O
Health	O
Analytic	O
electronic	O
health	O
record	O
database	O
as	O
reported	O
in	O
the	O
manuscript	O
and	O
were	O
purchased	O
by	O
Pfizer	O
from	O
Flatiron	O
Health	O
Inc.	O
,	O
an	O
independent	O
subsidiary	O
of	O
the	O
Roche	O
Group	O
.	O

Eligibility	O
criteria	O
aligned	O
with	O
those	O
of	O
the	O
PALOMA-2	O
trial	O
and	O
included	O
documented	O
HR+	O
(	O
estrogen	O
receptor	O
-	O
positive	O
[	O
ER+	O
]	O
or	O
progesterone	O
receptor	O
-	O
positive	O
)	O
and	O
HER2-disease	O
at	O
any	O
point	O
before	O
or	O
�	O
60	O
days	O
following	O
mBC	O
diagnosis	O
,	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
(	O
ECOG	O
PS	O
)	O
score	O
<3	O
within	O
30	O
days	O
of	O
mBC	O
diagnosis	O
,	O
and	O
initiation	O
of	O
[P1]	O
letrozole	O
[P2]	O
monotherapy	O
in	O
the	O
first	O
-	O
line	O
metastatic	O
setting	O
before	O
October	O
1	O
,	O
2015	O
.	O

Patients	O
who	O
had	O
received	O
previous	O
treatment	O
with	O
a	O
cyclin	O
-	O
dependent	O
kinase	O
4/6	O
inhibitor	O
or	O
who	O
had	O
another	O
primary	O
cancer	O
diagnosis	O
�	O
3	O
year	O
before	O
initiation	O
of	O
[P1]	O
letrozole	O
[P2]	O
monotherapy	O
were	O
excluded	O
.	O

The	O
RCT	O
cohort	O
comprised	O
women	O
from	O
the	O
[P1]	O
control	O
arm	O
[P2]	O
of	O
the	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
international	O
,	O
multicenter	O
,	O
phase	O
3	O
PALOMA-2	O
study	O
(	O
NCT01740427	O
)	O
(	O
Fig	O
1	O
)	O
.	O

In	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
cohort	O
,	O
patients	O
were	O
treated	O
with	O
letrozole	O
monotherapy	O
per	O
approved	O
labeling	O
and	O
treating	O
physicians	O
'	O
clinical	O
judgment	O
.	O

In	O
the	O
real	O
-	O
world	O
cohort	O
,	O
patients	O
were	O
treated	O
with	O
[P1]	O
letrozole	O
[P2]	O
monotherapy	O
per	O
approved	O
labeling	O
and	O
treating	O
physicians	O
'	O
clinical	O
judgment	O
.	O

In	O
the	O
[P1]	O
RCT	O
cohort	O
[P2]	O
,	O
women	O
received	O
letrozole	O
(	O
2.5	O
mg	O
once	O
daily	O
,	O
administered	O
orally	O
)	O
plus	O
placebo	O
per	O
the	O
PALOMA-2	O
study	O
protocol	O
.	O
[	O

In	O
the	O
RCT	O
cohort	O
,	O
women	O
received	O
[P1]	O
letrozole	O
[P2]	O
(	O
2.5	B-arm_dosage
mg	I-arm_dosage
once	I-arm_dosage
daily	I-arm_dosage
,	I-arm_dosage
administered	I-arm_dosage
orally	I-arm_dosage
)	O
plus	O
placebo	O
per	O
the	O
PALOMA-2	O
study	O
protocol	O
.	O
[	O

In	O
the	O
RCT	O
cohort	O
,	O
women	O
received	O
letrozole	O
(	O
2.5	B-arm_dosage
mg	I-arm_dosage
once	I-arm_dosage
daily	I-arm_dosage
,	I-arm_dosage
administered	I-arm_dosage
orally	I-arm_dosage
)	O
plus	O
[P1]	O
placebo	O
[P2]	O
per	O
the	O
PALOMA-2	O
study	O
protocol	O
.	O
[	O

For	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
cohort	O
,	O
tumor	O
burden	O
was	O
assessed	O
during	O
routine	O
clinical	O
visits	O
for	O
patients	O
with	O
HR+/HER2−	O
mBC	O
.	O
[	O

Study	O
origin	O
(	O
[P1]	O
real	O
-	O
world	O
[P2]	O
or	O
PALOMA-2	O
)	O
was	O
used	O
as	O
an	O
outcome	O
and	O
potential	O
baseline	O
confounders	O
were	O
included	O
as	O
covariates	O
,	O
having	O
been	O
selected	O
based	O
on	O
the	O
authors	O
'	O
clinical	O
judgment	O
.	O

September	O
30	O
,	O
2016	O
for	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
cohort	O
and	O
February	O
26	O
,	O
2016	O
for	O
PALOMA-2	O
.	O

The	O
duration	O
of	O
first	O
line	O
[P1]	O
letrozole	O
[P2]	O
therapy	O
was	O
abstracted	O
using	O
Flatiron	O
business	O
rules	O
applied	O
to	O
patient	O
EHRs	O
for	O
the	O
real	O
-	O
world	O
cohort	O
.	O

The	O
duration	O
of	O
first	O
line	O
letrozole	O
therapy	O
was	O
abstracted	O
using	O
Flatiron	O
business	O
rules	O
applied	O
to	O
patient	O
EHRs	O
for	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
cohort	O
.	O

The	O
Kaplan	O
-	O
Meier	O
method	O
was	O
used	O
to	O
estimate	O
median	B-arm_efficacy_metric
rwPFS	I-arm_efficacy_metric
and	O
RECIST	B-arm_efficacy_metric
-	I-arm_efficacy_metric
based	I-arm_efficacy_metric
PFS	I-arm_efficacy_metric
for	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
and	O
PALOMA-2	O
cohorts	O
,	O
respectively	O
.	O

Between	O
January	O
1	O
,	O
2011	O
,	O
and	O
September	O
30	O
,	O
2015	O
(	O
data	O
cutoff	O
,	O
September	O
30	O
,	O
2016	O
)	O
,	O
107	O
women	O
initiated	O
[P1]	O
letrozole	O
[P2]	O
monotherapy	O
and	O
met	O
the	O
eligibility	O
criteria	O
for	O
inclusion	O
in	O
the	O

In	O
PALOMA-2	O
,	O
222	O
patients	O
were	O
randomized	O
to	O
treatment	O
with	O
[P1]	O
letrozole	O
[P2]	O
plus	O
placebo	O
between	O
February	O
2013	O
and	O
July	O
2014	O
(	O
cutoff	O
date	O
for	O
final	O
analysis	O
,	O
February	O
26	O
,	O
2016	O
)	O
and	O
were	O
included	O
in	O
the	O
unadjusted	O
RCT	O
cohort	O
(	O
Table	O
3	O
)	O
.	O

In	O
PALOMA-2	O
,	O
222	O
patients	O
were	O
randomized	O
to	O
treatment	O
with	O
letrozole	O
plus	O
[P1]	O
placebo	O
[P2]	O
between	O
February	O
2013	O
and	O
July	O
2014	O
(	O
cutoff	O
date	O
for	O
final	O
analysis	O
,	O
February	O
26	O
,	O
2016	O
)	O
and	O
were	O
included	O
in	O
the	O
unadjusted	O
RCT	O
cohort	O
(	O
Table	O
3	O
)	O
.	O

Rounding	O
to	O
the	O
nearest	O
whole	O
number	O
,	O
the	O
IPTWadjusted	O
number	O
was	O
116	O
for	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
cohort	O
and	O
207	O
for	O
the	O
RCT	O
cohort	O
(	O
Table	O
4	O
)	O
.	O

Unweighted	O
,	O
unadjusted	O
demographic	O
and	O
clinical	O
characteristics	O
of	O
the	O
2	O
cohorts	O
were	O
broadly	O
comparable	O
,	O
although	O
patients	O
in	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
cohort	O
were	O
older	O
(	O
mean	O
age	O
68.6	O
vs	O
60.6	O
y	O
in	O
PALOMA-2	O
)	O
,	O
more	O
racially	O
diverse	O
,	O
had	O
poorer	O
performance	O
status	O
(	O
12.1	O
%	O
vs	O
1.4	O
%	O
with	O
ECOG	O
PS	O
2	O
)	O
,	O
and	O
were	O
more	O
likely	O
to	O
have	O
stage	O
IV	O
disease	O
(	O
39.3	O
%	O
vs	O
32.4	O
%	O
)	O
and	O
boneonly	O
metastases	O
(	O
29.9	O
%	O
vs	O
21.6	O
%	O
)	O
at	O
diagnosis	O
(	O
Table	O
3	O
)	O
.	O

Unweighted	O
,	O
unadjusted	O
demographic	O
and	O
clinical	O
characteristics	O
of	O
the	O
2	O
cohorts	O
were	O
broadly	O
comparable	O
,	O
although	O
patients	O
in	O
the	O
real	O
-	O
world	O
cohort	O
were	O
older	O
(	O
mean	O
age	O
68.6	O
vs	O
60.6	O
y	O
in	O
[P1]	O
PALOMA-2	O
[P2]	O
)	O
,	O
more	O
racially	O
diverse	O
,	O
had	O
poorer	O
performance	O
status	O
(	O
12.1	O
%	O
vs	O
1.4	O
%	O
with	O
ECOG	O
PS	O
2	O
)	O
,	O
and	O
were	O
more	O
likely	O
to	O
have	O
stage	O
IV	O
disease	O
(	O
39.3	O
%	O
vs	O
32.4	O
%	O
)	O
and	O
boneonly	O
metastases	O
(	O
29.9	O
%	O
vs	O
21.6	O
%	O
)	O
at	O
diagnosis	O
(	O
Table	O
3	O
)	O
.	O

As	O
all	O
but	O
1	O
of	O
these	O
patients	O
-	O
a	O
54	O
year	O
old	O
-	O
were	O
over	O
the	O
age	O
of	O
60	O
,	O
these	O
patients	O
were	O
retained	O
in	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
dataset	O
(	O
Table	O
3	O
)	O
.	O

Because	O
[P1]	O
letrozole	O
[P2]	O
is	O
specifically	O
contraindicated	O
in	O
women	O
of	O
premenopausal	O
status	O
it	O
could	O
reasonably	O
be	O
inferred	O
that	O
these	O
patients	O
met	O
the	O
criteria	O
for	O
medically	O
confirmed	O
postmenopausal	O
status	O
or	O
were	O
in	O
medically	O
-	O
induced	O
menopause	O
as	O
a	O
result	O
of	O
ovarian	O
suppression	O
per	O
current	O
treatment	O
guidelines	O
and	O
standard	O
practice	O
.	O

Using	O
unadjusted	O
and	O
unweighted	O
patient	O
data	O
for	O
the	O
2	O
cohorts	O
,	O
median	O
rwPFS	O
was	O
18.7	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
14.6	I-arm_efficacy_results
-	I-arm_efficacy_results
24.1	I-arm_efficacy_results
)	I-arm_efficacy_results
for	O
[P1]	O
real	O
-	O
world	O
[P2]	O
patients	O
and	O
PFS	O
was	O
14.5	O
months	O
(	O
95	O
%	O
CI	O
,	O
12.9	O
-	O
17.1	O
)	O
for	O
PALOMA-2	O
patients	O
(	O
hazard	O
ratio	O
,	O
1.38	O
[	O
95	O
%	O
CI	O
,	O
1.00	O
-	O
1.91	O
]	O
)	O
;	O

Using	O
unadjusted	O
and	O
unweighted	O
patient	O
data	O
for	O
the	O
2	O
cohorts	O
,	O
median	B-arm_efficacy_metric
rwPFS	I-arm_efficacy_metric
was	O
18.7	O
months	O
(	O
95	O
%	O
CI	O
,	O
14.6	O
-	O
24.1	O
)	O
for	O
real	O
-	O
world	O
patients	O
and	O
PFS	B-arm_efficacy_metric
was	O
14.5	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
12.9	I-arm_efficacy_results
-	I-arm_efficacy_results
17.1	I-arm_efficacy_results
)	I-arm_efficacy_results
for	O
[P1]	O
PALOMA-2	O
[P2]	O
patients	O
(	B-arm_efficacy_results
hazard	I-arm_efficacy_results
ratio	I-arm_efficacy_results
,	I-arm_efficacy_results
1.38	I-arm_efficacy_results
[	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
1.00	I-arm_efficacy_results
-	I-arm_efficacy_results
1.91	I-arm_efficacy_results
]	I-arm_efficacy_results
)	I-arm_efficacy_results
;	I-arm_efficacy_results

Median	B-arm_efficacy_metric
rwPFS	I-arm_efficacy_metric
was	O
longer	O
than	O
PFS	B-arm_efficacy_metric
in	O
the	O
[P1]	O
PALOMA-2	O
[P2]	O
cohort	O
,	O
potentially	O
reflecting	O
the	O
higher	O
proportion	O
of	O
patients	O
with	O
bone	O
-	O
only	O
disease	O
in	O
this	O
group	O
.	O

18.4	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
12.8	I-arm_efficacy_results
-	I-arm_efficacy_results
23.3	I-arm_efficacy_results
)	I-arm_efficacy_results
for	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
group	O
and	O
16.6	O
months	O
(	O
95	O
%	O
CI	O
,	O
13.7	O
-	O
22.2	O
)	O
for	O
the	O
PALOMA-2	O
group	O
(	O
Fig	O
2B	O
)	O
.	O

18.4	O
months	O
(	O
95	O
%	O
CI	O
,	O
12.8	O
-	O
23.3	O
)	O
for	O
the	O
real	O
-	O
world	O
group	O
and	O
16.6	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
13.7	I-arm_efficacy_results
-	I-arm_efficacy_results
22.2	I-arm_efficacy_results
)	I-arm_efficacy_results
for	O
the	O
[P1]	O
PALOMA-2	O
[P2]	O
group	O
(	O
Fig	O
2B	O
)	O
.	O

The	O
hazard	O
ratio	O
using	O
[P1]	O
real	O
-	O
world	O
[P2]	O
data	O
as	O
reference	O
was	O
1.04	B-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
0.69	I-arm_efficacy_results
-	I-arm_efficacy_results
1.56	I-arm_efficacy_results
)	I-arm_efficacy_results
.	I-arm_efficacy_results

The	O
unweighted	O
,	O
unadjusted	O
mean	O
(	O
standard	O
deviation	O
[	O
SD	O
]	O
)	O
duration	O
of	O
first	O
-	O
line	O
[P1]	O
letrozole	O
[P2]	O
treatment	O
was	O
slightly	O
longer	O
among	O
patients	O
in	O
the	O
real	O
-	O
world	O
cohort	O
than	O
in	O
the	O
PALOMA-2	O
cohort	O
:	O

The	O
unweighted	O
,	O
unadjusted	O
mean	O
(	O
standard	O
deviation	O
[	O
SD	O
]	O
)	O
duration	O
of	O
first	O
-	O
line	O
letrozole	O
treatment	O
was	O
slightly	O
longer	O
among	O
patients	O
in	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
cohort	O
than	O
in	O
the	O
PALOMA-2	O
cohort	O
:	O

The	O
unweighted	O
,	O
unadjusted	O
mean	O
(	O
standard	O
deviation	O
[	O
SD	O
]	O
)	O
duration	O
of	O
first	O
-	O
line	O
letrozole	O
treatment	O
was	O
slightly	O
longer	O
among	O
patients	O
in	O
the	O
real	O
-	O
world	O
cohort	O
than	O
in	O
the	O
[P1]	O
PALOMA-2	O
[P2]	O
cohort	O
:	O

After	O
IPTW	O
-	O
adjustment	O
,	O
mean	O
(	O
SD	O
)	O
duration	O
of	O
treatment	O
was	O
13.3	O
months	O
(	O
11.1	O
)	O
in	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
cohort	O
and	O
14.6	O
months	O
(	O
8.9	O
)	O
in	O
the	O
PALOMA-2	O
group	O
,	O
with	O
a	O
reduction	O
in	O
standardized	O
difference	O
to	O
0.1242	O
(	O
Table	O
5	O
)	O
.	O

After	O
IPTW	O
-	O
adjustment	O
,	O
mean	O
(	O
SD	O
)	O
duration	O
of	O
treatment	O
was	O
13.3	O
months	O
(	O
11.1	O
)	O
in	O
the	O
real	O
-	O
world	O
cohort	O
and	O
14.6	O
months	O
(	O
8.9	O
)	O
in	O
the	O
[P1]	O
PALOMA-2	O
[P2]	O
group	O
,	O
with	O
a	O
reduction	O
in	O
standardized	O
difference	O
to	O
0.1242	O
(	O
Table	O
5	O
)	O
.	O

Discontinuations	O
due	O
to	O
treatment	O
-	O
related	O
adverse	O
events	O
or	O
toxicity	O
were	O
relatively	O
low	O
,	O
and	O
were	O
reported	O
more	O
frequently	O
among	O
patients	O
in	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
cohort	O
than	O
in	O
the	O
PALOMA-2	O
cohort	O
(	O
6.5	O
%	O
and	O
4.1	O
%	O
,	O
respectively	O
)	O
(	O
Table	O
6	O
)	O
.	O

Discontinuations	O
due	O
to	O
treatment	O
-	O
related	O
adverse	O
events	O
or	O
toxicity	O
were	O
relatively	O
low	O
,	O
and	O
were	O
reported	O
more	O
frequently	O
among	O
patients	O
in	O
the	O
real	O
-	O
world	O
cohort	O
than	O
in	O
the	O
[P1]	O
PALOMA-2	O
[P2]	O
cohort	O
(	O
6.5	O
%	O
and	O
4.1	O
%	O
,	O
respectively	O
)	O
(	O
Table	O
6	O
)	O
.	O

Complete	O
tumor	O
response	O
was	O
more	O
frequently	O
reported	O
in	O
the	O
unadjusted	O
[P1]	O
real	O
-	O
world	O
[P2]	O
cohort	O
(	O
11.2	O
%	O
)	O
than	O
the	O
unadjusted	O
PALOMA-2	O
group	O
(	O
2.3	O
%	O
)	O
(	O
Fig	O
3B	O
)	O
.	O

Complete	O
tumor	O
response	O
was	O
more	O
frequently	O
reported	O
in	O
the	O
unadjusted	O
real	O
-	O
world	O
cohort	O
(	O
11.2	O
%	O
)	O
than	O
the	O
unadjusted	O
[P1]	O
PALOMA-2	O
[P2]	O
group	O
(	O
2.3	O
%	O
)	O
(	O
Fig	O
3B	O
)	O
.	O

Of	O
note	O
,	O
22.4	O
%	O
of	O
patients	O
in	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
cohort	O
had	O
no	O
tumor	O
assessments	O
recorded	O
during	O
a	O
mean	O
5.8	O
months	O
of	O
first	O
line	O
therapy	O
.	O

22,23]-in	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
cohort	O
.	O

In	O
addition	O
,	O
in	O
contrast	O
to	O
the	O
global	O
[P1]	O
PALOMA-2	O
[P2]	O
study	O
,	O
patients	O
in	O
the	O
real	O
-	O
world	O
cohort	O
are	O
all	O
from	O
the	O
US	O
and	O
receive	O
care	O
in	O
routine	O
clinical	O
settings	O
,	O
which	O
may	O
have	O
contributed	O
to	O
the	O
observed	O
differences	O
in	O
the	O
frequency	O
of	O
tumor	O
assessments	O
.	O

In	O
addition	O
,	O
in	O
contrast	O
to	O
the	O
global	O
PALOMA-2	O
study	O
,	O
patients	O
in	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
cohort	O
are	O
all	O
from	O
the	O
US	O
and	O
receive	O
care	O
in	O
routine	O
clinical	O
settings	O
,	O
which	O
may	O
have	O
contributed	O
to	O
the	O
observed	O
differences	O
in	O
the	O
frequency	O
of	O
tumor	O
assessments	O
.	O

The	O
[P1]	O
PALOMA-2	O
[P2]	O
protocol	O
specified	O
that	O
tumor	O
assessments	O
be	O
conducted	O
every	O
12	O
weeks	O
,	O
while	O
in	O
the	O
real	O
-	O
world	O
cohort	O
scans	O
were	O
ordered	O
at	O
the	O
discretion	O
of	O
the	O
treating	O
physician	O
.	O

The	O
PALOMA-2	O
protocol	O
specified	O
that	O
tumor	O
assessments	O
be	O
conducted	O
every	O
12	O
weeks	O
,	O
while	O
in	O
the	O
[P1]	O
real	O
-	O
world	O
[P2]	O
cohort	O
scans	O
were	O
ordered	O
at	O
the	O
discretion	O
of	O
the	O
treating	O
physician	O
.	O

RWD	O
,	O
[P1]	O
real	O
-	O
world	O
[P2]	O
data	O
.	O